Continue reading Early this year, the FDA approved hyaluronidase-facilitated subcutaneous immunoglobulin (SCIG) 10% (Hyqvia) for maintenance therapy to prevent relapses in CIDP. Promising phase II ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated ...

Shire’s (formerly Baxter Healthcare Corporation) HyQvia is administered as a single monthly SC injection for the majority of patients, compared with weekly multisite injections required for SC ...

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers ...

Meanwhile, Takeda recently won a U.S. CIDP approval for its subcutaneous immune globulin treatment HyQvia in January, portending a potential showdown later this year should Vyvgart Hytrulo pass ...

Takeda’s blockbuster Entyvio has racked up a new indication in its subcutaneous formulation. The FDA approved the subcutaneous form as a maintenance therapy for patients with moderately to ...

OSAKA, Japan & CAMBRIDGE, Mass., January 29, 2024--Takeda announced that the EC approved HYQVIA as maintenance therapy in patients of all ages with CIDP after stabilization with IVIG. Cognizant ...